GEDII 2020

Cascais has been for a few days the Portuguese capital of Inflammatory Bowel Disease. The city has hosted the last Annual Meeting of the Portuguese Inflammatory Bowel Disease Study Group (GEDII 2020).   From 22 to 24 January, professionals from different countries who are dedicated to the study of these diseases gathered here to share experiences, exchange knowledge, and learn about new approaches to ulcerative colitis and Crohn’s disease. 

As part of our commitment to help the healthcare professionals to reduce inflammation in patients with Ulcerative Colitis, Adacyte Therapeutics has not missed the appointment. During two intense days we have worked to make known the clinical benefit and the safety profile of Adacolumn. This non-pharmacological treatment has been proven to reduce the inflammation by removing leukocytes from the blood circulation. This reduces the inflammatory load without the risk of experiencing the side effects attributed to medicines. Our team has attended mainly to young and veteran doctors, gastroenterologists, pediatricians, surgeons and nurses.  

GEDII 2020 Meeting Content

This interdisciplinary meeting was attended by many other profiles of professionals, both national and international. The first day of GEDII 2020, the second edition of the Educational Workshop organized by Young GEDII took place. It has also been the chosen day to celebrate the Advanced Course on perianal Crohn’s disease. On this occasion, the multidisciplinary approach required by the topic has been highlighted. As in previous editions, nursing has also been given a prominent place. The Nursing Meeting has been dedicated to the main role of the Gastroenterology Day Hospital which is so necessary in addressing IBD.

Finally, from the second day, the main meeting was held. In this meeting the specificities of pediatric pathology, the problem of comorbidities, the developments in the field of new medicines and, last but not least, the new therapeutic strategies were addressed. The microbiome, an expression of a promising future for our patients, took a place of honor.

Recent News